home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Modern Drug Discovery and Development

 
  June 07, 2004  
     
 


GTCbio, San Diego, CA
Oct. 18-19, 2004


The human morbidity and mortality are largely dependent on the ever-elusive world of drug discovery and development. Over the past few years, there has been an explosion of scientific and clinical advances, both within chemical and biological driven areas. Consequently, this new wave of interdisciplinary technology has led to the identification and in vivo validation of new drug targets. In addition, to the discovery of new small molecule and protein based therapeutic agents for major forms of human diseases. In this regard, GTCbio is holding an annual conference on “Modern Drug Discovery and Development” on October 18-19, 2004 in San Diego, CA.

This event will be organized into five sessions: I. Drug design and lead optimization; II. Biological Processes and Process Development; III. Metabolic and Toxicological Processes; IV. Biological Products, Chemical and Biological Information, and V. Proteomics and Pharmacogenomics. A total of 27 speakers have been confirmed to present at this two-day event. Presenting companies include industry-leaders such as Merck, Schering-Plough, Boehringer Ingelheim GmbH, Johnson & Johnson, Aventis Pharmaceuticals, Novartis Research Foundation, IBM Life Sciences, and many more.

“Modern Drug Discovery & Development” will deliver the information you need to stay up to speed, as the meeting will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. It will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need. Specifically, it is suitable for Research Investigators, Group Leaders, Vice Presidents, Directors, Project Managers, Manufacturers, Presidents of R&D, Medical Directors, Global Project Managers, Marketers and Venture Capitalists.

In addition, the event will provide a great opportunity for companies to expose products and services. Networking times have been allocated to enhance the exchange of information between technology developers and end-users.

 
 
Organized by: GTCbio
Invited Speakers: Daniel Wyss
Schering-Plough Research Institute

Guenter Trummlitz
Boehringer Ingelheim GmbH

James Guy Breitenbucher
Johnson & Johnson PRD

Reinhold Tacke
Institute fur Anorganische Chemie

Sophie-Dorothee Clas
Merck Frosst Canada & Co.

Rainer Netzer
Evotech OAI

Amy Rubinstein
Zygogen LLC

Dr. Dale Dhanoa
Predix Pharmaceuticals

Ivan Rich
HemoGenix LLC

James Kang
Univ. of Louisville School of Medicine

John Cashman
Human BioMolecular Research Institute

Chris King
Merck & Co.

Fraser Wright
Avigen Inc.

Howard Kaufman
Columbia Univ. College of Physicians & Surgeons

Leodevico Ilag
Xerion Pharmaceuticals AG

Pierre Beauparlant
Gemin X Biotechnologies Inc

David Edwards
Accelrys Inc.

Joseph D’Antuono
ROW2 Technologies Inc.

Mariana Vaschetto
Accelrys Cambridge LTD

Peter Gund
IBM Life Sciences Pharmaceutical R&D Solutions

Ilya Kupershmidt
Silicon Genetics

Ruben Abagyan
Genomics Institute of the Novartis Research Foundation

 
Deadline for Abstracts: July 15, 2004
 
Registration: Commercial - $1495.00 Academic/gov - $695.00 Early registration discount 20% off if you register before July 11. 10% off if you register before August 11. Register 3 persons, and the 4th person attends free!
E-mail: mddd@gtcbio.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.